Missing is record of money FDA receives from Pfizer annually.
The Food and Drug Administration (FDA) released a huge batch of documents last week related to its approval process for the COVID-19 vaccine. The documents were released under court order after Federal Judge Mark Pittman ordered the FDA in January to release 55,000 pages per month.
The batch of documents released on March 1st contain some disturbing revelations, such as the FDA and Pfizer having prior knowledge of thousands of adverse side effects resulting from the vaccine.
But one thing starkly missing from the documents is a record of the money the FDA receives from Pfizer annually.
A couple of documents note the $2,875,842 Pfizer paid the FDA as a Prescription Drug User Fee, which is standard and listed on the FDA’s website.
But we’re looking for the hundreds of millions of dollars the FDA receives from Pfizer each year and there’s no record of it.
And we know the FDA receives that money because they said so.
Last month, Frontline News reported on a bombshell video from Project Veritas that showed shocking admissions from an FDA executive.
Christopher Cole, the FDA’s executive officer of countermeasures initiatives, unwittingly admitted to the undercover Project Veritas reporter that the FDA receives money to approve certain products.
“The drug companies, the food companies, the vaccine companies, they pay us hundreds of millions of dollars a year to hire and keep the reviewers to approve their products,” said Cole.
The FDA’s review teams generally consist of project managers, medical officers, pharmacology/toxicology specialists, statisticians, clinical pharmacologists, biopharmaceutics specialists, and chemists/biologists/microbiologists.
Included among the released documents is a Transfer of Obligations, which lists the sponsor responsibilities transferred from BioNTech SE to Pfizer Inc. Most of the responsibilities have to do with the clinical investigators contracted to assess the vaccine.
But the very last responsibility is written only as “annual reviews”.
Unlike investigators and clinical researchers, FDA drug reviewers are not outsourced or independently contracted.